Aurinia Pharmaceuticals Inc.
AUPH
$7.17
-$0.42-5.53%
| Weiss Ratings | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C- | |||
| Rating Factors | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.06 | |||
| Price History | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -13.57% | |||
| 30-Day Total Return | -10.77% | |||
| 60-Day Total Return | -11.21% | |||
| 90-Day Total Return | -17.74% | |||
| Year to Date Total Return | -18.30% | |||
| 1-Year Total Return | 43.88% | |||
| 2-Year Total Return | -27.41% | |||
| 3-Year Total Return | -40.19% | |||
| 5-Year Total Return | -51.72% | |||
| 52-Week High % Change | -28.87% | |||
| 52-Week Low % Change | 61.15% | |||
| Price | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.67 | |||
| 52-Week Low Price | $4.71 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Dec 10, 2024 | |||
| Valuation | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.04B | |||
| Enterprise Value | 763.33M | |||
| Price/Earnings (TTM) | 187.41 | |||
| Earnings Per Share (TTM) | 0.04 | |||
| Earnings Per Share Growth | -107.41% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.77 | |||
| Price/Book (Q) | 2.83 | |||
| Enterprise Value/Revenue (TTM) | 3.25 | |||
| Price | $7.17 | |||
| Enterprise Value/EBITDA (TTM) | 23.88 | |||
| Enterprise Value/EBIT | 60.97 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 147.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 250-744-2487 | |||
| Address | #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 | |||
| Website | www.auriniapharma.com | |||
| Country | Canada | |||
| Year Founded | 1993 | |||
| Profitability | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 5.32% | |||
| Profit Margin | 2.44% | |||
| Management Effectiveness | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 1.42% | |||
| Return on Equity | 1.52% | |||
| Income Statement | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 235.13M | |||
| Total Revenue (TTM) | 235.13M | |||
| Revenue Per Share | $1.59 | |||
| Gross Profit (TTM) | 186.10M | |||
| EBITDA (TTM) | 31.96M | |||
| EBIT (TTM) | 12.52M | |||
| Net Income (TTM) | 5.75M | |||
| Net Income Avl. to Common (TTM) | 5.75M | |||
| Total Revenue Growth (Q YOY) | 32.76% | |||
| Earnings Growth (Q YOY) | 105.32% | |||
| EPS Diluted (TTM) | 0.04 | |||
| EPS Diluted Growth (Q YOY) | 105.37% | |||
| Balance Sheet | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 358.44M | |||
| Cash Per Share (Q) | $2.43 | |||
| Total Current Assets (Q) | 446.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 377.48M | |||
| Current Ratio (Q) | 4.568 | |||
| Book Value Per Share (Q) | $2.68 | |||
| Total Assets (Q) | 550.65M | |||
| Total Current Liabilities (Q) | 97.76M | |||
| Total Debt (Q) | 79.37M | |||
| Total Liabilities (Q) | 173.17M | |||
| Total Common Equity (Q) | 377.48M | |||
| Cash Flow | AUPH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 39.26M | |||
| Cash from Financing (TTM) | -49.09M | |||
| Net Change in Cash (TTM) | 34.56M | |||
| Levered Free Cash Flow (TTM) | 62.94M | |||
| Cash from Operations (TTM) | 44.39M | |||
